Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: Clinical and economic implications

Value in Health

Volumn 4, Issue 5, 2001, Pages 376-384

  Beth Devine, E ^a   Kowdley, Kris V ^a   Veenstra, David L ^a   Sullivan, Sean D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Adverse effect; Cost; Hepatitis C virus

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN;

ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0034795027     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.2001.45075.x     Document Type: Article

References (46)

1. The natural history of hepatitis C viral infection
2. Hepatitis C: Global prevalence
3. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
4. Hepatitis C: The clinical spectrum of disease
5. Liver transplantation for chronic viral hepatitis
6. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
7. Therapy of Hepatitis C: Overview
8. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis
9. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
10. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
11. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
12. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C - Relapsed and treatment-naïve patients
13. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation
14. Treatment of severe recurrent hepatitis C after liver transplantation with ribavirin plus interferonalpha
15. Long-term outcome of hepatitis C infection after liver transplantation
16. Epoetin use for ribavirin/interferon induced anemia in patients with hepatitis C
17. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C. A multicenter trial
18. Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon
19. A pilot study of ribavirin therapy for chronic hepatitis C
20. Ribavirin as therapy for chronic hepatitis C
21. Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study
22. Ribavirin treatment for chronic hepatitis C
23. Ribavirin and interferon-α combination therapy vs interferon-α alone in the retreatment of chronic hepatitis C. A randomized clinical trial
24. Hemolysis in patients being treated with combination Intron-A/Ribavirin for chronic hepatitis C (CHC) infection
25. The effect of interferon alfa and ribavirin combination therapy in naïve patients with chronic hepatitis C
26. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C
27. R-interferon alpha-2b/ribavirin combined therapy followed by lowdose r-interferon alfa-2b in chronic hepatitis C interferon nonresponders
28. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience
29. Initial experiences with interferon and ribavirin for hepatitis C; tolerability of treatment in an academic center
30. Interferon alpha-2b and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after interferon-alpha therapy: A randomized trial
31. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C
32. A randomized trial of ribavirin and interferon-α vs. interferon-α alone in patients with chronic hepatitis C who were nonresponders to a previous treatment
33. Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C
34. Sequential versus concomitant administration of ribavirin and interferon alfa n-3 in patients with chronic hepatitis C not responding to interferon alone: Results of a randomized controlled trial
35. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C
36. Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: A randomized trial
37. Low doses (600 mg/d) of ribavirin are superior to high doses (1000-1200 mg/d) with interferon for chronic hepatitis C. Results of a controlled, randomized, multicenter trial
38. Cost-effectiveness of 24 or 48 weeks of interferon α-2b alone or with ribavirin as initial treatment of chronic hepatitis C
39. Cost-effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C
40. Cost effectiveness of interferon α2b combined with ribavirin for the treatment of chronic hepatitis C
41. Side effect profile of combination with interferon alpha-2b (IFN) and ribavirin in a community-based clinical trial